BioNTech’s (BNTX) “Buy” Rating Reaffirmed at HC Wainwright

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $134.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 35.23% from the company’s previous close.

Several other equities analysts have also recently commented on BNTX. Citigroup reiterated a “buy” rating and set a $140.00 target price (down from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Canaccord Genuity Group reissued a “buy” rating and issued a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. Morgan Stanley reduced their price target on shares of BioNTech from $140.00 to $132.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 6th. Finally, BMO Capital Markets boosted their price objective on BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $142.08.

BioNTech Price Performance

BNTX opened at $99.09 on Thursday. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The firm has a market cap of $23.82 billion, a price-to-earnings ratio of -47.19 and a beta of 1.35. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $97.44 and a 200 day simple moving average of $108.60.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same period in the prior year, the company posted $1.90 EPS. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. Equities research analysts expect that BioNTech will post -3.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BNTX. Banque Cantonale Vaudoise acquired a new stake in BioNTech in the first quarter worth about $36,000. Jones Financial Companies Lllp lifted its stake in shares of BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after acquiring an additional 246 shares during the period. Banque Transatlantique SA bought a new position in shares of BioNTech in the first quarter valued at approximately $80,000. Quintet Private Bank Europe S.A. boosted its holdings in shares of BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after acquiring an additional 700 shares in the last quarter. Finally, Allianz SE acquired a new position in shares of BioNTech during the fourth quarter valued at approximately $90,000. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.